Paper41384153
Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.
Petrakis V and 6 others. Infez Med, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece. Papers, record 41384153. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41384153
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39612160 | Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study). | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/39612160 | PubMed |
| 2 | 32094127 | Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32094127 | PubMed |
| 3 | 36482958 | Antibiotic therapy for pan-drug-resistant infections. | Infez Med | 2022 | https://conductscience.org/library/papers/36482958 | PubMed |
| 4 | 26596941 | Mutant Alleles of lptD Increase the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/26596941 | PubMed |
| 5 | 34082265 | Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019. | Diagn Microbiol Infect Dis | 2021 | https://conductscience.org/library/papers/34082265 | PubMed |
| 6 | 31430370 | Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/31430370 | PubMed |
| 7 | 40858146 | Repopulate, not just decolonise-a microbial ecological strategy against multidrug resistance in intensive care units. | Lancet Microbe | 2025 | https://conductscience.org/library/papers/40858146 | PubMed |
| 8 | 32050434 | Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. | Antibiotics (Basel) | 2020 | https://conductscience.org/library/papers/32050434 | PubMed |
| 9 | 35136967 | Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/35136967 | PubMed |
| 10 | 1329641 | Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1329641 | PubMed |
| 11 | 32060929 | Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. | Pharmacotherapy | 2020 | https://conductscience.org/library/papers/32060929 | PubMed |
| 12 | 40212030 | Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/40212030 | PubMed |
| 13 | 34901302 | Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34901302 | PubMed |
| 14 | 32514525 | In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/32514525 | PubMed |
| 15 | 33058795 | Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. | Lancet Infect Dis | 2021 | https://conductscience.org/library/papers/33058795 | PubMed |
| 16 | 35065702 | Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. | Lancet | 2022 | https://conductscience.org/library/papers/35065702 | PubMed |
| 17 | 35146349 | Complicated carbapenem-resistant infections: a treatment pathway analysis in Italian sites. | Infez Med | 2021 | https://conductscience.org/library/papers/35146349 | PubMed |
| 18 | 35727059 | New Perspectives on Antimicrobial Agents: Imipenem-Relebactam. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35727059 | PubMed |
| 19 | 29230684 | Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. | Drugs | 2018 | https://conductscience.org/library/papers/29230684 | PubMed |
| 20 | 31740559 | Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/31740559 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41384153
GET https://conductscience.org/api/papers/v1/41384153/references?page=2